RGC20250919C7.5
RGC Sep 19 2025 7.50 Call (RGC250919C00007500)
option OPRA

we are an early-stage bioscience company that focuses on research, development and commercialization of tcm for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder ("adhd"), autism spectrum disorder ("asd") in infectious diseases such as covid-19. our goal is to improve the lives of adhd, asd and covid patients, their families and caregivers and become a market leader for the best tcm treatment globally.